Drug Profile
Research programme: antibody therapeutics - Adimab/Seagen
Alternative Names: CASC-674Latest Information Update: 15 Dec 2023
Price :
$50
*
At a glance
- Originator Adimab
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Dec 2023 Seagen has been acquired by Pfizer
- 28 Apr 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Oct 2020 Seattle Genetics is now called Seagen